Cargando…
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion
INTRODUCTION: Alzheimer’s disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most advanced therapeutic approach at present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in t...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630258/ https://www.ncbi.nlm.nih.gov/pubmed/37812325 http://dx.doi.org/10.1007/s40120-023-00541-1 |